COMPASS Pathways
- Market cap
- 1.62B
- P/E (TTM)i
- -3.08
- P/Bi
- 19.16
- EPSi
- -3.08
- Div yieldi
- 0.00%
- 52W posi
- 62%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Care Facilities
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| COMPASS Pathways (CMPS) | 1.62B | -3.08 | 19.16 | 0.00% |
| HCA Healthcare (HCA) | 95.08B | 14.73 | -14.32 | 0.68% |
| Tenet Healthcare (THC) | 20.92B | 10.04 | 4.49 | 0.00% |
| Encompass Health (EHC) | 12.08B | 19.95 | 4.65 | 0.62% |
| DaVita (DVA) | 11.28B | 14.57 | -14.74 | 0.00% |
| Fresenius Medical Care (FMS) | 11.01B | 11.14 | 0.78 | 4.13% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 28.9% above Morningstar's fair value estimate.
Fair value
Compass Pathways PLC is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 39% premium over our quantitative fair value estimate of $8.32 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.
The company's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 5.2%, which falls in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.
The firm's lack of growth is an additional cause for concern. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's revenue 5-year growth of 0%, for example, ranks in the bottom 20% compared with global peers. Weak trailing five-year revenue growth is disappointing and could indicate trouble generating future value for shareholders, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 07:31:01 · For reference only, not investment advice and not tailored to your situation.